BMS-986278
- Generic Name
- BMS-986278
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31N5O5
- CAS Number
- 2170126-74-4
- Unique Ingredient Identifier
- 4UN9AOU6G8
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis
Phase 1
Recruiting
- Conditions
- Kidney Failure, ChronicHealthy VolunteersRenal Impairment
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT06723535
- Locations
- 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸Local Institution - 0003, Miami, Florida, United States
🇺🇸Omega Research Group, LLC - Orlando, Orlando, Florida, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Phase 3
Recruiting
- Conditions
- Progressive Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1092
- Registration Number
- NCT06025578
- Locations
- 🇦🇷
Instituto del Buen Aire - Santa Fe, Santa Fe, Argentina
🇧🇷Santa Casa de Misericórdia de Porto Alegre - Hospital Sao Jose, Porto Alegre, RS, Brazil
🇬🇷University General Hospital of Heraklion, Heraklion, Iraklio Kritis, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath